Roche’s

Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…

Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…

Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease…

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…

Roche’s trastuzumab, capecitabine, and tucatinib combo more than doubled median survival to 10 months in HER2+ breast cancer…

Roches, Profitability 27.03.2026 – 05:26:51 | boerse-global.de Roche defends profits via AI and efficiency…

Roche reports strong Phase III lupus data for Gazyva and finalizes share conversion. The company also increased its…

Roches, Unwavering 12.03.2026 – 05:15:50 | boerse-global.de Roche shareholders re-elect Chairman Severin Schwan and…

Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…

Roche’s Petrelintide shows 9% net weight loss in Phase II, missing high expectations. Stock and partner Zealand Pharma…

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4,…

Roches, Strategic 05.03.2026 – 05:37:28 | boerse-global.de Roche reports mixed Phase III results for…

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc